Clinical Trials in Italy / NCT06431373
Active, not recruiting
Phase 3
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373 · tracked via the Priya Life Science Italy tracker
Condition(s) studied
Uveitis, PosteriorUveitis, IntermediateUveitis
Investigational drug(s) / intervention(s)
Brepocitinib PO QDPlacebo PO QD
Brepocitinib PO QD: Brepocitinib PO QD
Placebo PO QD: Placebo PO QD
Study summary
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Eligibility
Inclusion Criteria:
* Adult subjects (18-75 years old)
* Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
* Active uveitic disease in at least 1 eye
* Weight \> 40 kg with a body mass index ≤ 40 kg/m2
Exclusion Criteria:
Has confirmed or suspected current diagnosis of infectious uveitis History of or have:
1. Lymphoproliferative disorder
2. active malignancy
3. cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
4. thrombosis or cerebrovascular ischemic event disease within the last 12 months
5. a high risk for herpes zoster reactivation
6. active or recent infections
Primary outcome measure(s)
- Time to treatment failure on or after Period 1 Week 6 up to Period 1 Week 48 — 48 weeks
Trial sites (107)
| Facility | City | Region | Status |
|---|---|---|---|
| Clinical Trial Site | Phoenix | Arizona | |
| Clinical Trial Site | Phoenix | Arizona | |
| Clinical Trial Site | Bakersfield | California | |
| Clinical Trial Site | Beverly Hills | California | |
| Clinical Trial Site | Fullerton | California | |
| Clinical Trial Site | Irvine | California | |
| Clinical Trial Site | La Jolla | California | |
| Clinical Trial Site | Los Angeles | California | |
| Clinical Trial Site | Los Angeles | California | |
| Clinical Trial Site | Modesto | California | |
| Clinical Trial Site | Sacramento | California | |
| Clinical Trial Site | Aurora | Colorado | |
| Clinical Trial Site | Denver | Colorado | |
| Clinical Trial Site | Fort Lauderdale | Florida | |
| Clinical Trial Site | St. Petersburg | Florida | |
| Clinical Trial Site | Chicago | Illinois | |
| Clinical Trial Site | Oak Park | Illinois | |
| Clinical Trial Site | Carmel | Indiana | |
| Clinical Trial Site | Prairie Village | Kansas | |
| Clinical Trial Site | Baltimore | Maryland | |
| Clinical Trial Site | Boston | Massachusetts | |
| Clinical Trial Site | Waltham | Massachusetts | |
| Clinical Trial Site | Ann Arbor | Michigan | |
| Clinical Trial Site | Detroit | Michigan | |
| Clinical Trial Site | Detroit | Michigan | |
| Clinical Trial Site | Minneapolis | Minnesota | |
| Clinical Trial Site | Rochester | Minnesota | |
| Clinical Trial Site | St Louis | Missouri | |
| Clinical Trial Site | Omaha | Nebraska | |
| Clinical Trial Site | Palisades Park | New Jersey | |
| NYU Langone Health | New York | New York | |
| Clinical Trial Site | Rochester | New York | |
| Clinical Trial Site | Durham | North Carolina | |
| Clinical Trial Site | Winston-Salem | North Carolina | |
| Clinical Trial Site | Cleveland | Ohio | |
| Clinical Trial Site | Cleveland | Ohio | |
| Clinical Trial Site | Columbus | Ohio | |
| Clinical Trial Site | Portland | Oregon | |
| Clinical Trial Site | Portland | Oregon | |
| Clinical Trial Site | Erie | Pennsylvania |
+ 67 more sites — see the full list on the official registry below.
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06431373 on ClinicalTrials.gov ↗ ← All trials in Italy